Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.41 |
| ▸ | PPARA | Q07869 | 11/20 | 0.41 |
| ▸ | PPARD | Q03181 | 5/20 | 0.41 |
| ▸ | PTPRF | P10586 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | SRR | Q9GZT4 | 4/20 | 0.36 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6752433 | 0.94 | PPARG (0.44) | PPARGPPARAPPARDPTPRFPTPN2 | |
| SCHEMBL6750892 | 0.89 | PPARG (0.52) | PPARGPPARAPPARDPTPRFPTPN2 | |
| SCHEMBL6753188 | 0.89 | PPARG (0.54) | PPARGPPARAPPARD | |
| SCHEMBL6753186 | 0.88 | PPARG (0.46) | PPARGPPARAPPARDPTPRFPTPN2 | |
| SCHEMBL7516718 | 0.87 | PPARG (0.41) | PPARGPPARAPPARDPTPRFPTPN2 | |
| SCHEMBL6754566 | 0.85 | PPARG (0.44) | PPARGPPARAPPARDSRRPSAT1 | |
| SCHEMBL6752437 | 0.85 | PPARG (0.52) | PPARGPPARAPPARD | |
| SCHEMBL6748853 | 0.85 | PPARG (0.41) | PPARGPPARAPPARDPTPRFPTPN2 | |
| SCHEMBL6753211 | 0.83 | PPARG (0.56) | PPARGPPARAPPARD | |
| SCHEMBL6754562 | 0.83 | PPARG (0.48) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020065268-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-30 | — | — | US | claimed |
| US-20020065267-A1 | Compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-30 | — | — | US | claimed |
| US-20020061880-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-23 | — | — | US | claimed |
| US-20020061876-A1 | Compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-23 | — | — | US | claimed |
| US-20020055502-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-09 | — | — | US | claimed |
| US-6703401-B2 | USEFUL IN THE TREATMENT AND/OR PREVENTION OF CONDITIONS MEDIATED BY CLEAR RECEPTORS, IN PARTICULAR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR). | NOVO NORDISK A/S (DK) | 2004-03-09 | — | — | US | disclosed |
| US-20020065268-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-30 | — | — | US | disclosed |
| US-20020065267-A1 | Compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-30 | — | — | US | disclosed |
| US-20020061880-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-23 | — | — | US | disclosed |
| US-20020061876-A1 | Compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-23 | — | — | US | disclosed |
| US-20020055502-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-05-09 | — | — | US | disclosed |
| US-6365586-B1 | REDUCE BLOOD GLUCOSE AND TRIGLYCERIDE LEVELS AND ARE USEFUL FOR THERAPY OF AILMENTS AND DISORDERS SUCH AS DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2002-04-02 | — | — | US | disclosed |
| EP-1123297-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000023451-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061880-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
| US-20020065267-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20020061876-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20020055502-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
| US-20020065268-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.